Cargando…

The GÖTEBORG prostate cancer screening 2 trial: a prospective, randomised, population-based prostate cancer screening trial with prostate-specific antigen testing followed by magnetic resonance imaging of the prostate

OBJECTIVE: To describe the study design of the GÖTEBORG prostate cancer screening (PC) 2 (Göteborg-2), a prospective, randomised, population-based trial of PC screening. This trial evaluates whether prostate-specific antigen (PSA) testing followed by 3 Tesla prostate magnetic resonance imaging (MRI)...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kohestani, Kimia, Månsson, Marianne, Godtman, Rebecka Arnsrud, Stranne, Johan, Wallström, Jonas, Carlsson, Sigrid, Hellström, Mikael, Hugosson, Jonas
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8376217/ https://www.ncbi.nlm.nih.gov/pubmed/33612068 http://dx.doi.org/10.1080/21681805.2021.1881612

Ejemplares similares

Bi- or multiparametric MRI in a sequential screening program for prostate cancer with PSA followed by MRI? Results from the Göteborg prostate cancer screening 2 trial
por: Wallström, Jonas, et al.
Publicado: (2021)

Results from 22 years of Followup in the Göteborg Randomized Population-Based Prostate Cancer Screening Trial
por: Frånlund, Maria, et al.
Publicado: (2022)

Degree of Preservation of Neurovascular Bundles in Radical Prostatectomy and Recurrence of Prostate Cancer
por: Axén, Elin, et al.
Publicado: (2021)

Prostate cancer screening—when to start and how to screen?
por: Kohestani, Kimia, et al.
Publicado: (2018)

A panel of kallikrein markers can reduce unnecessary biopsy for prostate cancer: data from the European Randomized Study of Prostate Cancer Screening in Göteborg, Sweden
por: Vickers, Andrew J, et al.
Publicado: (2008)

Prostate Cancer Mortality in Areas With High and Low Prostate Cancer Incidence
por: Stattin, Pär, et al.
Publicado: (2014)

Influence of blood prostate specific antigen levels at age 60 on benefits and harms of prostate cancer screening: population based cohort study
por: Carlsson, Sigrid, et al.
Publicado: (2014)

Impact of cause of death adjudication on the results of the European prostate cancer screening trial
por: Walter, Stephen D, et al.
Publicado: (2017)

Association of Baseline Prostate-Specific Antigen Level With Long-term Diagnosis of Clinically Significant Prostate Cancer Among Patients Aged 55 to 60 Years: A Secondary Analysis of a Cohort in the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial
por: Kovac, Evan, et al.
Publicado: (2020)

Intervention-related Deaths in the European Randomized Study of Screening for Prostate Cancer
por: Godtman, Rebecka Arnsrud, et al.
Publicado: (2021)

Population‐based, nationwide registration of prostatectomies in Sweden
por: Cazzaniga, Walter, et al.
Publicado: (2019)

Outcomes in Localized Prostate Cancer: National Prostate Cancer Register of Sweden Follow-up Study
por: Stattin, Pär, et al.
Publicado: (2010)

Randomised prostate cancer screening trial: 20 year follow-up
por: Sandblom, Gabriel, et al.
Publicado: (2011)

Editorial Comment: A 16-yr Follow-up of the European Randomized study of Screening for Prostate Cancer
por: Hugosson, J, et al.
Publicado: (2020)

Height and risk of prostate cancer in the prostate, lung, colorectal, and ovarian cancer screening trial
por: Ahn, J, et al.
Publicado: (2009)

Lifetime Benefits and Harms of Prostate-Specific Antigen–Based Risk-Stratified Screening for Prostate Cancer
por: Heijnsdijk, Eveline A M, et al.
Publicado: (2020)

Rule-based versus probabilistic selection for active surveillance using three definitions of insignificant prostate cancer
por: Venderbos, Lionne D. F., et al.
Publicado: (2015)

Association of surgeon and hospital volume with short-term outcomes after robot-assisted radical prostatectomy: Nationwide, population-based study
por: Godtman, Rebecka Arnsrud, et al.
Publicado: (2021)

Adding free to total prostate-specific antigen levels in trials of prostate cancer screening
por: Wald, N J, et al.
Publicado: (2000)

Specificity of serum prostate-specific antigen determination in the Finnish prostate cancer screening trial
por: Määttänen, L, et al.
Publicado: (2007)

Prostate cancer risk and nonsteroidal antiinflammatory drug use in the Finnish prostate cancer screening trial
por: Veitonmäki, T, et al.
Publicado: (2014)

Diabetes mellitus and prostate cancer risk in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial
por: Leitzmann, Michael F., et al.
Publicado: (2008)

Prostate cancer screening
por: Eastham, James
Publicado: (2017)

Importance of prostate volume in the European Randomised Study of Screening for Prostate Cancer (ERSPC) risk calculators: results from the prostate biopsy collaborative group
por: Roobol, Monique J., et al.
Publicado: (2011)

Role of mpMRI of the prostate in screening for prostate cancer
por: Wallis, Christopher J. D., et al.
Publicado: (2017)

False-positive screening results in the Finnish prostate cancer screening trial
por: Kilpeläinen, T P, et al.
Publicado: (2010)

Prostate cancer incidence among finasteride and alpha-blocker users in the Finnish Prostate Cancer Screening Trial
por: Murtola, T J, et al.
Publicado: (2009)

Serum metabolomic profiling of prostate cancer risk in the prostate, lung, colorectal, and ovarian cancer screening trial
por: Huang, Jiaqi, et al.
Publicado: (2016)

Prostate Cancer – To screen, or not to screen, is that the question?
por: Rosser, Charles J
Publicado: (2008)

To screen or not to screen: the prostate cancer dilemma
por: Stone, Nelson N, et al.
Publicado: (2015)

Advice About Screening for Prostate Cancer With Prostate-Specific Antigen
por: Jean-Pierre, Gannel
Publicado: (2017)

The influence of prostate volume on clinical parameters in prostate cancer screening
por: Shan, Jiahao, et al.
Publicado: (2022)

Digoxin and prostate cancer survival in the Finnish Randomized Study of Screening for Prostate Cancer
por: Kaapu, Kalle J, et al.
Publicado: (2016)

Bioimpedance and chronoamperometry as an adjunct to prostate-specific antigen screening for prostate cancer
por: de Abreu, Darci Schiavon
Publicado: (2011)

Overdetection, overtreatment and costs in prostate-specific antigen screening for prostate cancer
por: Heijnsdijk, E A M, et al.
Publicado: (2009)

Prostate cancer screening with prostate-specific antigen: A guide to the guidelines
por: Cabarkapa, Sonja, et al.
Publicado: (2016)

Gene‒Prostate-Specific-Antigen-Guided Personalized Screening for Prostate Cancer
por: Yang, Teng-Kai, et al.
Publicado: (2019)

Prostate-Specific Antigen Screening and Recent Increases in Advanced Prostate Cancer
por: Nyame, Yaw A, et al.
Publicado: (2020)

Beyond Prostate Specific Antigen: New Prostate Cancer Screening Options
por: Narain, Tushar Aditya, et al.
Publicado: (2022)

Prostate MRI versus PSA screening for prostate cancer detection (the MVP Study): a randomised clinical trial
por: Nam, Robert, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_cvk79cnf9u31nrvimo9e6nnmer